Adding ivabradine to beta-blockers in chronic heart failure: Do not rest without lowering the resting heart rate sufficiently.
作者信息
Oomman Abraham, Bansal Manish
机构信息
Apollo Hospitals, 21, Greams Lane, Off Greams Road, Chennai, India.
Medanta- The Medicity, Sector 38, Gurgaon, 122001, India.
出版信息
Indian Heart J. 2018 Mar-Apr;70(2):201-203. doi: 10.1016/j.ihj.2018.03.009.
Abstract
摘要
相似文献
1
Adding ivabradine to beta-blockers in chronic heart failure: Do not rest without lowering the resting heart rate sufficiently.
Indian Heart J. 2018 Mar-Apr;70(2):201-203. doi: 10.1016/j.ihj.2018.03.009.
2
Ivabradine in heart failure: hope or hype?
Am J Cardiovasc Drugs. 2012 Dec 1;12(6):357-9. doi: 10.1007/BF03262470.
3
Heart rate reduction in heart failure: ivabradine or beta blockers?
Heart Fail Rev. 2013 Jul;18(4):517-28. doi: 10.1007/s10741-012-9347-6.
4
Ivabradine in heart failure: what about digoxin?
Lancet. 2008 Dec 20;372(9656):2113; author reply 2113-4. doi: 10.1016/S0140-6736(08)61923-6.
5
Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties.
Eur J Heart Fail. 2014 Jan;16(1):76-85. doi: 10.1093/eurjhf/hft129. Epub 2013 Dec 3.
6
[Heart rate reduction due to selective specific inhibition of the If current opens new possibilities in treatment of basic cardiovascular diseases].
Eksp Klin Farmakol. 2013;76(2):37-42.
7
[Combination therapy of beta blockers for heart failure].
Nihon Rinsho. 2007 May 28;65 Suppl 5:129-33.
8
Limited role for ivabradine in the treatment of chronic heart failure.
Heart. 2011 Dec;97(23):1961-6. doi: 10.1136/heartjnl-2011-300041. Epub 2011 Sep 13.
9
Future directions: what data do we need?
Adv Cardiol. 2006;43:106-111. doi: 10.1159/000095432.
10
Ivabradine for the treatment of chronic heart failure.
Expert Rev Cardiovasc Ther. 2016;14(5):553-61. doi: 10.1586/14779072.2016.1165092. Epub 2016 Mar 28.
引用本文的文献
1
CAR requires Gadd45β to promote phenobarbital-induced mouse liver tumors in early stage.
Front Oncol. 2023 Sep 7;13:1217847. doi: 10.3389/fonc.2023.1217847. eCollection 2023.
2
Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications.
Indian Heart J. 2018 Dec;70 Suppl 3(Suppl 3):S435-S441. doi: 10.1016/j.ihj.2018.08.008. Epub 2018 Aug 20.
本文引用的文献
1
Heart rate manipulation in dilated cardiomyopathy: Assessing the role of Ivabradine.
Indian Heart J. 2018 Mar-Apr;70(2):246-251. doi: 10.1016/j.ihj.2017.08.009. Epub 2017 Aug 16.
2
Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure.
J Am Coll Cardiol. 2017 Jun 20;69(24):2885-2896. doi: 10.1016/j.jacc.2017.04.001. Epub 2017 Apr 30.
3
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.
J Am Coll Cardiol. 2017 Aug 8;70(6):776-803. doi: 10.1016/j.jacc.2017.04.025. Epub 2017 Apr 28.
4
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20.
5
Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF): A randomised study.
Int J Cardiol. 2016 Aug 15;217:7-11. doi: 10.1016/j.ijcard.2016.04.136. Epub 2016 Apr 19.
6
Head-to-Head Comparison of Global Longitudinal Strain Measurements among Nine Different Vendors: The EACVI/ASE Inter-Vendor Comparison Study.
J Am Soc Echocardiogr. 2015 Oct;28(10):1171-1181, e2. doi: 10.1016/j.echo.2015.06.011. Epub 2015 Jul 23.
7
Effect of Combining Ivabradine and β-Blockers: Focus on the Use of Carvedilol in the SHIFT Population.
Cardiology. 2015;131(4):218-24. doi: 10.1159/000380812. Epub 2015 May 12.
8
Heart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?
Eur J Heart Fail. 2012 Jul;14(7):737-47. doi: 10.1093/eurjhf/hfs060. Epub 2012 May 22.
9
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
J Am Coll Cardiol. 2012 May 29;59(22):1938-45. doi: 10.1016/j.jacc.2012.01.020.
10
Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study.
Clin Res Cardiol. 2013 Jan;102(1):11-22. doi: 10.1007/s00392-012-0467-8. Epub 2012 May 11.
Zotero 插件